335 related articles for article (PubMed ID: 10027309)
1. In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.
van der Veen AH; Seynhaeve AL; Breurs J; Nooijen PT; Marquet RL; Eggermont AM
Br J Cancer; 1999 Feb; 79(3-4):433-9. PubMed ID: 10027309
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.
de Wilt JH; Manusama ER; van Etten B; van Tiel ST; Jorna AS; Seynhaeve AL; ten Hagen TL; Eggermont AM
Br J Cancer; 2000 Nov; 83(9):1176-82. PubMed ID: 11027431
[TBL] [Abstract][Full Text] [Related]
3. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
4. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
van der Veen AH; de Wilt JH; Eggermont AM; van Tiel ST; Seynhaeve AL; ten Hagen TL
Br J Cancer; 2000 Feb; 82(4):973-80. PubMed ID: 10732774
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.
Brunstein F; Hoving S; Seynhaeve AL; van Tiel ST; Guetens G; de Bruijn EA; Eggermont AM; ten Hagen TL
J Natl Cancer Inst; 2004 Nov; 96(21):1603-10. PubMed ID: 15523089
[TBL] [Abstract][Full Text] [Related]
6. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
7. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
Furrer M; Altermatt HJ; Ris HB; Althaus U; Rüegg C; Liénard D; Lejeune FJ
Melanoma Res; 1997 Aug; 7 Suppl 2():S43-9. PubMed ID: 9578416
[TBL] [Abstract][Full Text] [Related]
8. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.
de Wilt JH; ten Hagen TL; de Boeck G; van Tiel ST; de Bruijn EA; Eggermont AM
Br J Cancer; 2000 Mar; 82(5):1000-3. PubMed ID: 10737379
[TBL] [Abstract][Full Text] [Related]
9. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats.
de Wilt JH; Soma G; ten Hagen TL; Kanou J; Takagi K; Nooijen PT; Seynhaevel AL; Eggermont AM
Anticancer Res; 2000; 20(5B):3491-6. PubMed ID: 11131652
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
[TBL] [Abstract][Full Text] [Related]
12. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.
Hoving S; Seynhaeve AL; van Tiel ST; aan de Wiel-Ambagtsheer G; de Bruijn EA; Eggermont AM; ten Hagen TL
Anticancer Drugs; 2006 Sep; 17(8):949-59. PubMed ID: 16940805
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
Hoving S; Brunstein F; aan de Wiel-Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
Cancer Res; 2005 May; 65(10):4300-8. PubMed ID: 15899822
[TBL] [Abstract][Full Text] [Related]
14. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.
Nooijen PT; Manusama ER; Eggermont AM; Schalkwijk L; Stavast J; Marquet RL; de Waal RM; Ruiter DJ
Br J Cancer; 1996 Dec; 74(12):1908-15. PubMed ID: 8980389
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.
Taeger G; Grabellus F; Podleska LE; Müller S; Ruchholtz S
Int J Hyperthermia; 2008 May; 24(3):193-203. PubMed ID: 18392998
[TBL] [Abstract][Full Text] [Related]
17. Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study.
Gutman M; Sofer D; Lev-Chelouche D; Merimsky O; Klausner JM
Invasion Metastasis; 1997; 17(4):169-75. PubMed ID: 9778589
[TBL] [Abstract][Full Text] [Related]
18. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion.
van Etten B; de Vries MR; van IJken MG; Lans TE; Guetens G; Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
Br J Cancer; 2003 Jan; 88(2):314-9. PubMed ID: 12610519
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
20. The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results.
Fraker DL; Alexander HR
Melanoma Res; 1994 Mar; 4 Suppl 1():27-9. PubMed ID: 8038592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
